| |
| Trade Name | Optune Lua |
| Classification Name | electrical tumor treatment fields |
| Generic Name | electrical tumor treatment fields |
| Applicant |
| Novocure, GmbH |
| neuhofstrasse 21 |
| baar 6340 |
|
| HDE Number | H180002 |
| Date Received | 10/23/2018 |
| Decision Date | 05/23/2019 |
| Product Code | |
| Docket Number | 19M-2522 |
| Notice Date | 05/24/2019 |
| Advisory Committee |
Anesthesiology |
| Clinical Trials |
NCT02397928
|
| Supplement Type | hde original |
| Expedited Review Granted? | No |
| Combination Product | No |
Approval Order Statement Approval for the novottf™-100l system. This device is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (mpm) to be used concurrently with pemetrexed and platinum-based chemotherapy. |
| Approval Order | Approval Order |
| Summary | Summary of Safety And Probable Benefit |
| Labeling | Labeling Labeling Part 2 |
| Supplements: |
S001 S002 S003 S004 S005 S006 S007 S009 |